A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)

J1P-MC-KFAJ -

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Lupus (SLE)
What the trial is testing?
LY3471851
Could I receive a Placebo?
Yes
Enrollment Goal
291
Trial Dates
Aug 19, 2020 - Feb 16, 2023
How long will I be in the trial?
The study will last about 43 weeks and may include up to 17 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have had systemic lupus erythematosus (SLE or lupus) for at least 6 months

  • Participants must have currently active manifestations of lupus

  • Participants must have active arthritis and/or rash

Participants Must Not:

  • Participants must not have severe lupus nephritis

  • Participants must not have severe central nervous system lupus

  • Participants must not have or have had another serious medical condition

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources